NightstaRx closes $35 million Series B funding to advance Inherited Retinal Disease pipeline
Oxford University Innovation spinout NightstaRx Ltd (“Nightstar”), a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, has announced a $35 million Series B financing round.